title: Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats.
abstract: Leflunomide (HWA 486, a novel isoxazol derivative), shown to have potent immunosuppressant and antiinflammatory effects, was evaluated for its inhibitory and therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against rat glomerular basement membrane. Leflunomide was administered orally to rats at 0.5 and 2 mg/kg/day for 20 days from 2 days before injection of the rabbit antiserum and at 2 mg/kg/day for 14 days from 5 days after the antibody injection. The present study consisting of 2 experiments for inhibitory (I) and therapeutic (II) effects of leflunomide revealed the following effects at 2 mg/kg: in experiment I, significant decreases in (a) urinary total protein, (b) plasma total cholesterol and fibrinogen and (c) thymus weight, and decreased incidences of fibrin deposits in Bowman's space, adhesion of the glomerulus to Bowman's capsule and deposition of rat IgG and C3; and in experiment II, decreases in (a), (b) and (c), though smaller than in experiment I, and decreases deposition of rat C3. Thus, leflunomide had potent inhibitory and limited therapeutic effects on glomerulonephritis, suggesting that the compound is effective in inhibiting the onset and development of glomerulonephritis.
authors.affiliation: Pharma Research Laboratories, Hoechst Japan Limited, Saitama-ken.
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Inazu
authors.forename: K
authors.initials: K
authors.lastname: Gotoh
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001485:Basement Membrane / Q000276:immunology*; D002455:Cell Division; D003176:Complement C3 / Q000032:analysis; D005337:Fibrin / Q000032:analysis; D005455:Fluorescent Antibody Technique; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007106:Immune Sera; D007074:Immunoglobulin G / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000473:pathology; D000077339:Leflunomide; D008297:Male; D010503:Periodic Acid-Schiff Reaction; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003176:Complement C3; D007106:Immune Sera; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D005337:Fibrin; D000077339:Leflunomide